Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131


Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, Stokes JC, Julier P, Iveson C, Duvvuri R, McConkey CC; VICTOR Trial Group.

N Engl J Med. 2007 Jul 26;357(4):360-9.


Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators.

N Engl J Med. 2005 Mar 17;352(11):1092-102. Epub 2005 Feb 15. Erratum in: N Engl J Med. 2006 Jul 13;355(2):221.


A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.

Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG; APPROVe Trial Investigators.

Gastroenterology. 2006 Dec;131(6):1674-82. Epub 2006 Sep 1.


Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.

Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ.

Circulation. 2001 Nov 6;104(19):2280-8.


The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups.

van Adelsberg J, Gann P, Ko AT, Damber JE, Logothetis C, Marberger M, Schmitz-Drager BJ, Tubaro A, Harms CJ, Roehrborn C.

Curr Med Res Opin. 2007 Sep;23(9):2063-70.


Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.

Lanas A, Baron JA, Sandler RS, Horgan K, Bolognese J, Oxenius B, Quan H, Watson D, Cook TJ, Schoen R, Burke C, Loftus S, Niv Y, Ridell R, Morton D, Bresalier R.

Gastroenterology. 2007 Feb;132(2):490-7. Epub 2006 Nov 10.


Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial.

Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson ER, Demets DL.

Lancet. 2008 Nov 15;372(9651):1756-64. doi: 10.1016/S0140-6736(08)61490-7. Epub 2008 Oct 14. Erratum in: Lancet. 2008 Nov 15;372(9651):1732.


Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002.

Bottone FG Jr, Barry WT.

Curr Med Res Opin. 2009 Jun;25(6):1535-50. doi: 10.1185/03007990902953286.


Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.

Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, Grumett SA, Julier P, Iveson C, Yanagisawa Y, Warren B, Langman MJ, Kerr DJ.

J Clin Oncol. 2010 Oct 20;28(30):4575-80. doi: 10.1200/JCO.2010.29.6244. Epub 2010 Sep 13.


Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.

Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J; APC and PreSAP Trial Investigators.

Circulation. 2006 Sep 5;114(10):1028-35.


Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies.

Madigan D, Sigelman DW, Mayer JW, Furberg CD, Avorn J.

Am Heart J. 2012 Aug;164(2):186-93. doi: 10.1016/j.ahj.2012.05.002. Epub 2012 Jul 3.


Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators.

N Engl J Med. 2005 Mar 17;352(11):1071-80. Epub 2005 Feb 15.


The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.

Rahme E, Barkun AN, Toubouti Y, Bardou M.

Gastroenterology. 2003 Aug;125(2):404-12.


Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.

Lévesque LE, Brophy JM, Zhang B.

CMAJ. 2006 May 23;174(11):1563-9. Epub 2006 May 2.


Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.

Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S.

Arthritis Rheum. 2006 May;54(5):1378-89.


Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.

White WB, Faich G, Borer JS, Makuch RW.

Am J Cardiol. 2003 Aug 15;92(4):411-8.


A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE.

N Engl J Med. 2005 Mar 31;352(13):1293-304. Epub 2005 Mar 7.

Supplemental Content

Support Center